Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.36 USD
4.19 B USD
61.16 B USD
1.77 B
About AbbVie Inc.
Sector
Industry
CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
IPO date
Jan 2, 2013
Identifiers
3
ISIN US00287Y1091
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Related stocks
ABBV Moderate Bull Holding Strong Breakout ZoneNYSE:ABBV 28/02/2026
💰 231.02
🟢 Moderate BULL 16.23% at 1.39x
🟢(58.1%):🔴(41.9%) ⏳Clarity:54%
Retrace:-0.5% Bounce:3.2% 5.9x 💥 BO+
Bulls are holding the edge here but this is not an aggressive setup. The multi-timeframe count shows 36 green against 24 red across 112 signals, with the higher timefra
ABBVIE A -25% correction is the norm at this point.AbbVie Inc. (ABBV) has topped on its historic 13-year Channel Up and since its October 2025 All Time High (ATH), which was a Higher High for the pattern, it has been trading sideways at best.
This is a strong indication of a potential long-term correction, the likes of which we've been seeing cycli
abbv building strengthas we can see abbv is in a bullish channel.
we are starting to form a bull flag inside this channel.
if we don't break down from this channel, we have a possible target at the top of the channel @275
simple annalist with support and resistant shows us.
we have support at 215
if price hits target
AbbVie in Descending ChannelAfter a strong impulsive rally (black trendline leg), price entered a descending parallel channel, indicating a corrective phase rather than a confirmed trend reversal — at least for now.
Current price: ~231
Price is testing the upper boundary of the descending channel.
🔎 Structure Overview
• Prio
AbbVie in Descending ChannelThe chart shows AbbVie Inc. (ABBV) on the daily timeframe.
After a strong impulsive rally (black trendline leg), price entered a descending parallel channel, indicating a corrective phase rather than a confirmed trend reversal — at least for now.
Current price: ~231
Price is testing the upper boun
ABBV Will Fly Once This HappensABBV Will Fly Once This Happens
NYSE:ABBV is one of those incredible companies, not just because of what they do, but how they do it. They have consistently ranked among the best for employee well-being while successfully bringing to market some of the most patent-protected biotech drugs, such a
AbbVie Inside a Falling ChannelAbbVie is currently trading inside a descending channel, following a strong impulsive bullish move. This structure suggests a controlled correction rather than a trend reversal, at least for now.
Price is oscillating around the midline of the channel and near the moving average, indicating short-te
AbbVie tests $225 as buyers step in ahead of catalysts:Current Price: 223.01 (Analysis was generated on Monday Morning)
Direction: LONG
Confidence level: 58%(Limited volume of trader commentary but consistent focus on $219 support and price holding above key moving averages supports a cautious long bias.)
Targets
Target 1: 225.00
Target 2: 226.00
St
ABBV Stock Analysis [1D TF]
Fundamental/Market Context
AbbVie (ABBV) continues to benefit from a diversified portfolio led by strong immunology and oncology franchises. Recent earnings have generally topped expectations, supporting confidence in cash flow and dividend sustainability, while pipeline catalysts provide medium-t
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of ABBV is 227.68 USD — it has decreased by −0.36% in the past 24 hours. Watch AbbVie Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange AbbVie Inc. stocks are traded under the ticker ABBV.
ABBV stock has fallen by −3.15% compared to the previous week, the month change is a 1.24% rise, over the last year AbbVie Inc. has showed a 5.09% increase.
We've gathered analysts' opinions on AbbVie Inc. future price: according to them, ABBV price has a max estimate of 328.00 USD and a min estimate of 205.00 USD. Watch ABBV chart and read a more detailed AbbVie Inc. stock forecast: see what analysts think of AbbVie Inc. and suggest that you do with its stocks.
ABBV reached its all-time high on Oct 1, 2025 with the price of 244.81 USD, and its all-time low was 32.51 USD and was reached on Dec 17, 2012. View more price dynamics on ABBV chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ABBV stock is 1.77% volatile and has beta coefficient of 0.36. Track AbbVie Inc. stock price on the chart and check out the list of the most volatile stocks — is AbbVie Inc. there?
Today AbbVie Inc. has the market capitalization of 401.39 B, it has increased by 5.12% over the last week.
Yes, you can track AbbVie Inc. financials in yearly and quarterly reports right on TradingView.
AbbVie Inc. is going to release the next earnings report on Apr 24, 2026. Keep track of upcoming events with our Earnings Calendar.
ABBV earnings for the last quarter are 2.71 USD per share, whereas the estimation was 2.65 USD resulting in a 2.15% surprise. The estimated earnings for the next quarter are 3.01 USD per share. See more details about AbbVie Inc. earnings.
AbbVie Inc. revenue for the last quarter amounts to 16.62 B USD, despite the estimated figure of 16.41 B USD. In the next quarter, revenue is expected to reach 14.72 B USD.
ABBV net income for the last quarter is 1.81 B USD, while the quarter before that showed 176.00 M USD of net income which accounts for 0.00% change. Track more AbbVie Inc. financial stats to get the full picture.
Yes, ABBV dividends are paid quarterly. The last dividend per share was 1.73 USD. As of today, Dividend Yield (TTM)% is 2.93%. Tracking AbbVie Inc. dividends might help you take more informed decisions.
AbbVie Inc. dividend yield was 2.91% in 2025, and payout ratio reached 281.66%. The year before the numbers were 3.54% and 263.15% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Mar 12, 2026, the company has 57 K employees. See our rating of the largest employees — is AbbVie Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbbVie Inc. EBITDA is 28.27 B USD, and current EBITDA margin is 47.50%. See more stats in AbbVie Inc. financial statements.
Like other stocks, ABBV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbbVie Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbbVie Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbbVie Inc. stock shows the buy signal. See more of AbbVie Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.









